Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mylan Launches Advair Generic Wixela At 70% Discount To GSK's Branded Drug List Price

Executive Summary

Two weeks after the product's approval, Mylan finally has launched Wixela and revealed a big price cut for the asthma and COPD medicine over the brand; the actual savings for patients remains dependent on payer negotiations and other factors.

Advertisement

Related Content

HHS' 2018 Greatest Hits: Azar Touts Record FDA Generic Approvals, Drug Pricing And Opioid Actions
Mylan’s Nod For US Advair Rival Puts It A Year Ahead Of The Pack
Mylan Sees Generic Advair Marathon Nearing FDA Finish Line
Mylan To Explore Strategic Options, Claiming Investors Have Failed To Appreciate The Value

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124656

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel